Even though it has shown its potential as a therapeutic target for AD through many studies, the failure of pan-JNK inhibitors in clinical trials has brought our attention to the development of highly selective JNK3 inhibitors for AD therapeutics [11]. Here, MAPK10 is linked to Alzheimer disease.